Idaho State Police Forensic Services

Approval for Quality System Controlled Documents



Section Five Quality Assurance

Quality Assurance Measures - Urine and Blood Toxicology 5.8

5.8.1 BACKGROUND

The quality assurance measures applied towards analysis of toxicological samples promote confidence in results.

5.8.2 **SCOPE**

This analytical method addresses general acceptance requirements for qualitative and quantitative analysis data obtained through analysis by gas chromatography equipped with a nitrogen phospherus (NPD) or a mass Requirements for analysis with other selective detective (MSD). instrumentation are addressed in relevant analytical methods.

5.8.3

5.8.4

EQUIPMENT AND SUPPLIES
Refer to specific analytical method.

REAGENTS
Refer to appropriate analytical method as well as manual section 5.12 for solution preparation instructions. solution preparation instructions.

5.8.5 INSTRUMENT OU ASSURANCE

Instrument Maintenance 5.8.5.1

> Replacement parts and cleaning supplies required for GC-MSD and GC-NPD maintenance should be stocked to reduce the time that an instrument is offline. Refer to manufacturer's hardcopy or electronic instrument manuals and/or hardcopy or on-line catalog for ordering information.

5.8.5.1.2 Refer to manufacturer's hardcopy or electronic instrument manuals for maintenance indicators and instructions.

5.8.5.2 MSD Tuning

An Autotune must be performed on a weekly basis. All parameters for the Autotune must fall within ranges defined by the manufacturer.

5.8.5.3 **Instrument Performance Monitoring**

	5.8.5.3.1	A test mix to monitor instrument performance must be analyzed a minimum of once a month.
	5.8.5.3.2	The TIC and the MS data for each compound purported to be present in test mix must be printed to demonstrate the presence of acceptable instrument performance.
	5.8.5.3.3	To monitor deterioration in instrument performance, compare the data for the test mix for a newly installed column and/or cleaned source with subsequent runs.
	5.8.5.3.4	Examine data to verify that all compounds are detected with consistent retention time, resolution, peak shape symmetry and signal abundance.
	5.8.5.3.5	Use data to determine when instrument maintenance must be performed.
	5.8.5.3.6	If the test mix is used for <i>Operation Verification</i> as described in 5.8.5.4, an additional test mix need not be analyzed as long as the monthly requirement is met.
	5.8.5.3.7	Data for test mix must be centrally stored.
5.8.5.4	Operation Ve 5.8.5.4.1	rification At the beginning of an analysis sequence the analyst
	of Mco	must run a sample that verifies the instrument's performance.
operto	5.8.5.4.2	The sample may be a test mix or analysis control. The data must be evaluated as indicated in 5.8.5.3.
640be	5.8.5.3.3	The TIC and the MS data for each compound purported to be present in test mix or analysis control must be printed to demonstrate the presence of acceptable instrument performance.
	5.8.5.4.4	The data from this verification sample must be centrally stored.
CARADIT	z ninen an av	ION OUALITY ASSUBANCE

5.8.6 SAMPLE PREPARATION QUALITY ASSURANCE

5.8.6.1 Qualitative Analysis

5.8.6.1.1 Non-extracted Reference Material

5.8.6.1.1.1 Reference material must be prepared

and analyzed as designated in appropriate analytical method.

5.8.6.1.1.2

Acquired data must be comparable to authentication data. No significant differences in GC-MS data must be apparent.

5.8.6.1.2 Matrix Controls

5.8.6.1.2.1

Ouality controls are to be prepared and analyzed as designated in the appropriate analytical method.

5.8.6.1.2.2

Positive controls should exhibit proper retention time and mass spectrat characteristics for compounds of interest.

5.8.6.1.2.3

controls be should for compound(s) of interest and interfering substances.

Solvent Blanks
538.5.1.3.1 Le be

An appropriate solvent blank should be run between sample extracts.

If the solvent blank contains a reportable analyte of interest, the corrected area of the analyte peak must be a minimum of 10 times stronger than the corresponding peak in the blank preceding it. Ideally, no contamination should be apparent.

Reportable is defined as a complete fragmentation pattern at the appropriate retention time. Analytes of interest include, but are not routinely analytes limited to. reported.

5.8.5.1.3.4

significant contamination present, as discussed in 5.8.5.1.3.2, evaluate the analysis of a newly obtained solvent blank and the sample extract in question. If the

3 of 5

Issued: 05-07-2007 5.8 - OA Measures - Urine and Blood- Rev 5.doc Issuing Authority: Quality Manager

contamination is still apparent, instrument troubleshoot the of determine the source In addition, the contamination. sample in question should be reextracted prior to reanalysis rectified instrument.

5.8.6.2 Quantitative Analysis

Quality measures are optimized for the analytes in question and are addressed in each individual quantitative analytical method.

- 5.8.6.3 Distribution of Quality Data
 - Original data for matrix controls will be stored in a designated central location in the laboratory where the analysis was performed.
 - 5.8.6.3.2 Copies of all quality assurance control data need not be placed in each case file except those required under 5.8.6.3.3.
 - 5.8.6.3.3 Copies of analytical reference material used to substantiate the identification of each drug compound must be included in each case file if not otherwise indicated in the relevant analytical method.

5.8.7 REFERENCES

- 5.8.7.1 Wir Chen, N.B. Cody, J.T., Garriott, J.C., Foltz, R.L., and et al., Report of the Ad hoc Committee on Forensic GC/MS: Recommended guidelines for forensic GC/MS procedures in toxicology laboratory associated with offices of medical examiners and/or coroners, J. Foren. Sci, 236 (35): 236-242, 1990.
- 5.8.7.2 Goldberger, B.A., Huestis, M.A., Wilkins, D.G., Commonly practiced quality control and quality assurance procedures for gas chromatograph/mass spectrometry analysis in forensic urine drugtesting laboratories, For Sci Review, 9(2): 60-79, 1997.
- 5.8.7.3 SOFT/AAFS Forensic Toxicology Laboratory Guidelines, 2002

Revision History

Section Five Quality Assurance

5.8 Quality Assurance Measures – Urine and Blood Toxicology

Revision #	Issue Date	History
		Original Issue Clarifications, Updated Clarification of authentication process. Reformatted, scope broadened.
0	10-18-2002	Original Issue
1	04-16-2003	Clarifications, Updated.
2 3	07-23-2003	Clarification of authentication process.
3	03-09-2005	Reformatted, scope broadened.
4	05-24-2006	Clarifications, authentication process moved to SOP 5.10.
5	05-07-2007	Updated (A measures and reformatting.
•		Weekly tuning introduced.
Propert	y of Idaho nitions	Clarification of authentication process. Reformatted, scope broadened. Clarifications, authentication process moved to SOP 5.10. Updated QA measures and reformatting. Weekly tuning introduced.